I t is estimated that approximately 564 830
Americans died from cancer in 2006, corresponda a ing to over 1500 deaths per day, with lung cancer being among the ten leading cancer types. 1 A total of 1.2 million cancer deaths worldwide were attributed to lung cancer in 2002. 2 Smoking mainly causes lung cancer; 95% of patients with lung cancer are smokers. The mortality is high, with a 5ayear crude survival from 5% to 15%. Oneaquarter of the patients have small cell lung cancer and three quarters have nonasmall cell lung cancer (NSCLC), mainly squamous cell carcinoma, ada a enocarcinoma and large cell carcinoma. 3 Only a minority of patients with NSCLC are suita a able candidates for radical curative treatment; the maa a jority present with locally advanced or metastatic disa a ease at diagnosis and can obtain only a modest survival benefit from palliative platinumabased chemotherapy with or without radiotherapy. The prognosis for such patients is poor, with 5ayear survival rates of less than 10%. 4 Median survival for patients with locally ada a vanced disease or metastatic disease is 18 and 9 months, respectively. 5 For firstaline treatment of patients with unresectable advanced (Stage IIIb/IV) NSCLC, platia a numabased doublets are standard. 6, 7 The introduction of thirdageneration cytotoxic agents (such as paclitaxel, docetaxel, gemcitabine, vinorelbine and irinotecan) achieved improvements in tumor response and tolera a ability, but only modest improvements in survival, and it may be that chemotherapy has reached its maximum potential.
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Recent therapies for NSCLC that are under intense development target novel cellular entities, such as epia a dermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), 3 in normal tissues, and in almost every type of human tumor. Its expression is seen in alveolar macrophages, normal bronchiolar and differentiated columnar epia a thelial cells. 15 VEGF increases permeability by inducing endothelial fenestrations, thus allowing the leakage of plasma proteins into the extravascular tissue and proa a moting the creation of a fibrinalike microenvironment. 16 This microenvironment serves as the foundation for neovascularization, tumor growth, propagation, and metastasis. 17 Several studies indicate a correlation bea a tween VEGF expression, microvessel density (MVD) and poor prognosis in patients with NSCLC. 18 Youn et al reported that a high VEGF level correlated with high MVD, short survival and early postoperative relapse. 19 Ushijima et al found that high MVD values carried an especially poor prognosis when associated with a high expression of VEGF. 20 Bevacizumab (Avastin, F. HoffmannaLa Roche Ltd, Basel, Switzerland) is a recombinant humanized monoclonal antibody against VEGF. 21 Preclinical in vivo models demonstrate that bevacizumab inhiba a its growth of a variety of human cancer cell lines in a doseadependent manner. 22, 23 In addition, by eliminating excess VEGF, newly formed tumor vessels become less permeable, resulting in a reduction of interstitial presa a sure. It has been shown that the latter effect increases the diffusion of chemotherapeutic drugs in the tumor and perhaps potentiates their activity. 24 A randomized phased II study suggested the benefit of adding bevacizumab to standard chemotherapy for advanced NSCLC. 10 These results led to the incorporaa a tion of bevacizumab in the treatment of such patients at our institution when possible, before its final regulatory approval by the European authorities. Subsequently, the confirmatory phase III study was published, further supporting our practice. 23 We present hereby a retroa a spective analysis of the outcomes of our early cohort of NSCLC patients who received bevacizumab, aiming at better characterizing the feasibility, safety and efficacy of bevacizumab in such patients.
PATIENTS AND METHODS
The study population included male and female paa a tients 18 years of age or older who had stage IIIB or IV, advanced or recurrent metastatic NSCLC, and had received a bevacizumab combination, on a compassiona a ate basis, before its regulatory approval. The decision on the use of bevacizumab was based on clinical judgment and the permission for such a compassionate use by the Hellenic Drug Organization (the central regulatory agency). Patients who had received prior therapy with various chemotherapeutic regimens were included in the study; however, the majority of patients were chea a motherapy naïve. There was no intentional exclusion of patients from receiving bevacizumab other than serious coamorbid conditions, according to clinical judgment and centrally located squamous cell cancer.
Good clinical practice standards applied to our cohort. Pretreatment evaluation included a complete medical history, physical examination and standard laboratory examinations (full blood count, biochemical profile, prothrombin time, international normalized raa a tio, and partial thromboplastin time). CT or MRI of the chest, abdomen and brain were taken, and performance status was assessed according to Eastern Cooperative Oncology Group (ECOG) guidelines. A complete blood count was obtained regularly. An interim medical history, physical examination, and the laboratory tests listed above were repeated prior to the start of each cycle of therapy. Tumor assessment with imaging was performed every 6 weeks while on therapy and every 8 weeks after completion; responses were determined by the investigators according to WHO criteria; 25 stability required a minimum of 12 weeks.
Treatment plan
Every patient received bevacizumab 15 mg/kg on day 1 every 3 weeks, along with standard chemotherapeutic regimens including carboplatinapaclitaxel, carboplatina pemetrexed, platinum with gemcitabine, docetaxelabased chemotherapy, and erlotinib. Because bevacizumab was not approved for NSCLC during the study period, it was commercially provided after communication with regulaa a tory authorities and the patient' s insurance company. Its use was justified by existing clinical evidence, as the best available palliative treatment, on a compassionate basis. Finally, growth factor was administered on a peraneed baa a sis and relatively liberally; 17 patients received leukocyte colonyastimulating factor at some point.
Statistical analysis
The primary objective of the study was to assess the impact of bevacizumab in combination with various chemotherapeutic regimens on patient outcomes in a preliminary manner. Main endpoints included the dea a scription of toxicity outcomes on all patients; secondary endpoints included the median overall (OS) and proa a gressionafree survival (PFS) rates and clinical response rates of patients receiving firstaline treatment. Data are expressed as median and minimumamaximum for continuous variables and as percentages for categorical data. OS and PFS were estimated with the Kaplana Meier productalimit method. 26 All tests were twoasided with a 95% significance level. The statistical analysis was carried out using the statistical package SPSS vera a sion 15.00 (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA).
RESULTS

Patient characteristics
The 20 patients with NSCLC treated at our departa a ment between April 2005 and August 2007 and rea a viewed for this study included 16 (80%) males and 4 (20%) females with a median age of 54.5 years (range, 35a75 years) ( Table 1) . The majority of patients had stage IV disease. All patients had confirmed adenocara a cinoma of the lung with the exception of one patient who had relapsed after lobectomy with peripherally located squamous cell carcinoma and another who had adenoid cystic carcinoma. Due to local insurance rea a strictions, procurement of bevacizumab was feasible for approximately one quarter of the otherwise eligible patients who visited our clinic.
At therapy initiation, 17 patients (85%) were chea a motherapy naïve and therefore on firstaline treatment. The remaining 3 patients (15%) were on secondaline treatment. In addition to bevacizumab, 9 patients (45%) received a chemotherapeutic combination of carboplatin/paclitaxel, 3 patients (15%) a combination of carboplatin/pemetrexed, 3 patients (15%) received docetaxelabased chemotherapy, 2 patients (10%) rea a ceived a combination of platinum/gemcitabine, 1 patient (5%) received a combination of carboplatin/ gemcitabine, 1 patient (5%) received erlotinib, and 1 patient (5%) received a combination of cetuximab/ irinotecan. Three patients (15%) had an ECOG pera a formance status (PS) of 0, 11 patients (55%) had a PS of 1, 5 patients (25%) had a PS of 2 and 1 patient (5%) had a PS of 3. For all treated patients, the median number of therapy cycles administered was 6 (range, 1a18). The median followaup of this cohort was 6.1 months (range, 1a26).
Toxicity
In general, bevacizumab was well tolerated by most patients. No thrombotic events were noted. Grade 2 hypertension occurred in 3 patients. Uncomplicated Non estimable 2 11.8 Table 4 . Overall survival and progression-free survival (patients on first-line treatment (n=17).
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Median ( epistaxis was reported in 5 patients and one patient dea a veloped mild gingival bleeding. There were no episodes of febrile neutropenia or proteinuria (Table 2) . Overall, serious toxicity possibly related to bevacizumab admina a istration was observed in one case.
Response, overall survival and progression free survival rates Of the 17 patients on firstaline treatment, 2 patients (11.8%) achieved a complete response and 6 patients (35.3%) achieved a partial response (overall response rate, 47.1%). Stable disease was observed in 6 patients (35.3%) and 1 patient (5.9%) progressed (Table 3 ). The 1ayear overall survival rate was 52.4% and the median OS was 14 months (range, 4.8a23.2 months) ( Table 4 , Figure 1 ). The 12amonth PFS rate was 48.8% and the median PFS was 10.2 months (range, 4.3a16.1 months) ( Table 4 , Figure 2 ).
DISCUSSION
The benefit of adding bevacizumab to standard treata a ment for unresectable NSCLC is by now well docua a mented. In E4599, a phase III study of bevacizumab in NSCLC, Sandler et al showed that the median overa a all survival was 12.3 months in the group of patients who received paclitaxelacarboplatinabevacizumab, as compared to 10.3 months in the paclitaxelacarboplata a in group (P=.003). Survival rates were 51% in the paa a clitaxelacarboplatinabevacizumab group as compared to 44% in the paclitaxelacarboplatin group at 1 year and 23%, as compared to 15%, respectively, at 2 years. The median PFS was also significantly improved in the paclitaxelacarboplatinabevacizumab group (6.2 months, as compared with 4.5 months in the paclia a taxelacarboplatin group). Among 773 patients with measurable disease, the addition of bevacizumab to paclitaxel and carboplatin improved the response rate; 59 of 392 patients (15%) in the paclitaxelacara a boplatin group had a response, as compared with 133 of 381 patients (35%) in the paclitaxelacarboplatina bevacizumab group (P<.001).
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In another randomized, phase II trial by Johnson and associates comparing carboplatin and paclitaxel with or without bevacizumab at two dose levels (7.5 mg/kg versus 15mg mg/kg) in 99 patients with una a treated advanced or metastatic nonasmall cell lung cana a cer, higher response rates (31.5% versus 18.8%), longer median time to progression (7.4 versus 4.2 months, P=.023), and longer survival (17.7 versus 14.9 months, P=.63) were demonstrated in patients receiving the higheradose (15 mg/kg) bevacizumab. A total of 19 paa a tients originally receiving placebo with chemotherapy were crossed over to bevacizumab at the time of disease progression, with a 1ayear survival rate of 47%. 28, 29 The results of our uncontrolled and retrospective analysis of the compassionate use of bevacizumab in a cohort of patients with advanced NSCLC treated at our institution are consistent with the aboveadescribed benefit of bevacizumab in this population. The observed overall survival is in line with the report of the randoma a ized phase III study while the response rate observed is extremely encouraging and exceeds expectations. In addition, the durability of responses and the overa a all deceleration of the expected pace of the disease are particularly rewarding, and in retrospect justified the enthusiasm regarding the initiative to use bevacizumab regimens in our patients, before its regulatory approval. Apparently, this therapeutic option was facilitated by the experience of our center and our investigators in the use of bevacizumab in colon cancer patients, over the last 4 years.
Our study results are limited by the relatively small number of patients who received offalabel bevacizumab therapy for the treatment of NSCLC; thus any conclua a sions should be drawn with caution. Nevertheless, our study illustrates a preliminary experience in patients with lung cancer, in a real world clinical setting, outside the rigor and beyond the limitations of a restricted trial design. In fact, several of our patients would have been eliminated from clinical studies. Regarding the safety aspect of the regimen studied, our experience demona a strated a toxicity profile that did not diverge from the expected. In particular, although bevacizumab was prea a viously reported to increase the rate of neutropenia, there was no neutropenic complication in our cohort. This was certainly facilitated by the use of growth faca a tors, according to the judgment of the treating physia a cian. In addition, the incidence of hypertension was low and this complication was relatively easily managed. It is also noteworthy that one case of fatal pulmonary hemorrhage occurred several months after bevacizuma a ab discontinuation, and is of unclear causal relationship with its administration. That patient had suffered many complications and had received mediastinal irradiation at a site of a recent infection, notwithstanding the presa a ence of a foreign body, namely an esophageal stent. Fatal hemorrhages may occur in patients with lung cancer, even without the use of bevacizumab. Although the fatal hemorrhage may have not been related to bevacizumab per se, the development of the tracheoesophageal fistula on the basis of a pulmonary abscess may well be related. The proper healing of the esophageal wall adjacent to the abscess may have been impaired by the circulating bevacizumab and may have led to the formation of the fistula. Such a patient with centrally located lesions adjacent to major vessels might have been eliminated from certain clinical studies such as the AVAIL study, but he would have been included in the ECOG study. Nevertheless, despite concerns over pulmonary hemora a rhage in patients receiving bevacizumab in the E4599 study, 27 no statistically significant difference in pulmoa a nary hemorrhage between the two arms was proven.
Despite the unfortunate outcome of the one patient described, the addition of bevacizumab to standard chemotherapeutic regimens was otherwise well tolera a ated and appeared to yield highly beneficial outcomes for this cohort of patients. Thus, our experience is in agreement with the reports of previously conducted prospective studies, encouraging us to continue the use of bevacizumab in the adjuvant setting, in patients with nonasquamous, NSCLC. Nevertheless, confirmatory evidence from future welladesigned trials is warranted to precisely elucidate the beneficial role of bevacizumab in NSCLC.
